I'll give you the figures, but if you don't mind I'll just do a little preamble to that first.
We are, as far as I know, the only country that systematically looked at what the benefits could be as we got into this. We talk today about the cost of $10 billion; the same studies pointed repeatedly to $6 billion to $7 billion being saved each and every year. Those savings actually come in two tranches. The major savings come through cost avoidance, through preventing adverse drug reactions and keeping people out of expensive acute care beds.